HBsAg Hijacks TBK1 to Suppress IFN and Induce Autophagy

Chronic hepatitis B virus (HBV) infection remains a major cause of liver disease and hepatocellular carcinoma. The reference study by Luo and colleagues, published in Cell Death and Disease in 2025, examines how hepatitis B surface antigen (HBsAg) coordinates innate immune suppression with autophagy remodeling. Rather than describing HBsAg only as a structural component of the viral envelope, the study positions it as an active regulator of TANK-binding kinase 1 (TBK1), a signaling node that normally contributes to both antiviral interferon production and autophagy.

Study Background and Research Question

HBV infects hepatocytes and can establish long-term persistence despite recognition by host innate immune pathways. The virus encodes several proteins, including the surface, core, polymerase, and X proteins; HBsAg is produced in large, medium, and small forms that share the S domain but differ at their amino termini. In addition to supporting viral entry and particle secretion, HBsAg has been associated with immune escape.

Innate viral sensing commonly converges on adaptor proteins such as TRIF, MAVS, and STING, which facilitate TRAF3–TBK1–IRF3 signaling. Activated TBK1 phosphorylates IRF3, enabling its nuclear activity and the transcription of type I interferons, including interferon-β, as well as interferon-stimulated genes. TBK1 can also phosphorylate sequestosome-1, commonly called p62, thereby connecting pathogen sensing with autophagy regulation. This creates a potential biological branch point: TBK1 activity can support antiviral gene expression or influence autophagic processes depending on the molecular context.

The central question was therefore not simply whether HBV induces autophagy, but whether HBsAg mechanistically rewires TBK1 signaling so that antiviral interferon production is reduced while an autophagy state favorable to viral persistence is established. The study also asked whether the resulting autophagy was complete and degradative or instead represented an early, incomplete stage of the pathway.

Key Innovation from the Reference Study

The principal innovation is the identification of an HBsAg–TBK1 axis that separates two normally connected outputs of TBK1. According to the reference paper, HBsAg interacts with the kinase domain of TBK1. This interaction increases TBK1 dimerization but disrupts the association between TBK1 and IRF3. The result is an unusual signaling configuration in which TBK1 phosphorylation is enhanced, whereas IRF3 phosphorylation and downstream type I interferon signaling are depressed.

This finding refines the interpretation of kinase activation measurements. Increased TBK1 phosphorylation does not necessarily indicate effective antiviral signaling if the kinase is physically redirected away from IRF3. The study consequently frames TBK1 as a spatially and functionally partitioned signaling platform rather than a simple on–off switch.

A second innovation is the connection between this altered TBK1 complex and autophagy. HBsAg-enhanced TBK1 dimerization promoted p62 phosphorylation, which the authors found to be necessary for HBV-associated autophagy and viral replication. At the same time, HBsAg inhibited the SNAP29 promoter and blocked autophagosome–lysosome fusion. Thus, HBsAg appears to stimulate the formation or accumulation of autophagosomes while limiting their productive maturation. This distinction is important because autophagosome accumulation alone cannot establish increased autophagic degradation.

Methods and Experimental Design Insights

The experimental strategy was layered across molecular, cellular, pharmacological, animal, and human-tissue evidence. This structure strengthens the mechanistic argument because the study did not rely on a single fluorescent autophagy marker or one interferon assay.

At the molecular level, the investigators examined the physical relationship between HBsAg, TBK1, and IRF3 and mapped the relevant interaction to the TBK1 kinase domain. They assessed TBK1 dimerization and compared phosphorylation states of TBK1, IRF3, and p62. These experiments addressed both protein association and signaling output, which is necessary for distinguishing direct complex remodeling from a nonspecific change in kinase abundance.

At the functional level, the study measured type I interferon responses, including interferon-β signaling, alongside autophagy-related endpoints. The authors evaluated autophagosome accumulation, p62 phosphorylation, and autophagosome–lysosome fusion, while promoter analysis was used to investigate suppression of SNAP29 transcription. This combination is more informative than measuring LC3 or p62 abundance in isolation because it considers both autophagosome formation and downstream flux.

Pharmacological perturbation with BX795 was used to test whether TBK1 activity contributed to the HBsAg-dependent autophagy and replication phenotypes. In this context, BX795 functions as a pathway perturbant supporting the TBK1 interpretation; it should not be treated as proof that every observed effect is uniquely attributable to TBK1 because small-molecule kinase inhibitors can have additional targets. The authors then extended the analysis to HBsAg transgenic mice and liver samples from individuals with chronic HBV infection, testing whether suppressed interferon signaling and incomplete autophagy were detectable beyond the initial experimental system.

Protocol Parameters

• Mechanism comparison: Compare control and HBsAg-expressing conditions using paired measurements of TBK1 phosphorylation, TBK1 dimerization, IRF3 phosphorylation, and interferon-β output rather than relying on a single endpoint.
• Pharmacological interpretation: Use BX795 as a perturbational control for TBK1-linked signaling, with matched vehicle controls and, where possible, an orthogonal genetic or biochemical approach to test target specificity. The reference study supports the TBK1 connection, but exact concentrations and exposure times should be taken from its full Methods section.
• Autophagy assessment: Separate autophagosome accumulation from autophagic flux by combining formation markers with assays of lysosomal delivery, SNAP29 expression, and p62 behavior.
• Validation level: Treat cellular findings as mechanistic evidence and compare them with liver tissue from HBsAg models or chronic HBV infection to evaluate biological relevance in vivo.
• Replication readout: Relate changes in autophagy and interferon signaling to HBV replication measurements, because pathway modulation without a virological endpoint would not establish functional significance.

Core Findings and Why They Matter

The first major finding was that HBsAg suppressed type I interferon production while increasing TBK1 phosphorylation. This apparent contradiction is resolved by the observed disruption of TBK1–IRF3 complexes. HBsAg does not simply reduce TBK1 activity; it changes how activated TBK1 is used. Consequently, inhibition of interferon regulatory factor 3 activation can occur alongside an increase in a different TBK1-dependent output.

The second finding was that HBsAg-dependent TBK1 dimerization supported p62 phosphorylation and autophagy-associated phenotypes. BX795 experiments linked this TBK1-dependent activity to HBV-induced autophagy and replication. The result suggests that the virus may exploit a host kinase that normally participates in innate immune defense, redirecting it toward a state that helps maintain viral production or cellular adaptation.

The third finding concerned autophagy quality. HBsAg promoted autophagosome accumulation but impaired autophagosome–lysosome fusion through suppression of SNAP29 promoter activity. This pattern is consistent with incomplete autophagy rather than efficient terminal degradation. Biologically, incomplete autophagy could provide membrane structures or signaling conditions useful to HBV while avoiding the full degradative consequences of lysosomal fusion.

Finally, liver tissues from HBsAg transgenic mice and chronic HBV patients showed reduced interferon-β signaling and evidence of incomplete autophagy. These observations do not by themselves prove that the HBsAg–TBK1 mechanism is the only cause of chronic infection, but they provide important cross-system support. The study therefore links a defined molecular interaction with phenotypes observed in disease-relevant tissue.

Why this cross-domain matters, maturity, and limitations

The study is primarily an HBV innate-immunity investigation, but its use of BX795 also illustrates why researchers should distinguish compound identity from pathway assignment. BX795 is widely used as a PDK1 inhibitor and can also inhibit TBK1 and IKKε; the available product information describes these overlapping activities. PDK1-related work often concerns the PI3K/Akt/mTOR signaling pathway and cancer cell growth inhibition, whereas the reference paper uses BX795 to interrogate TBK1-dependent innate immune response modulation.

This cross-domain relationship is useful but not equivalent to evidence that PDK1 controls the HBsAg phenotype. The paper supports a TBK1-centered interpretation, while broader applications of BX795 in cancer or PI3K/Akt/mTOR studies require their own target-validation controls. The mechanistic bridge is therefore mature enough to guide assay design, but not to justify transferring conclusions between antiviral and cancer models without additional experiments.

Comparison with Existing Internal Articles

The internal article HBsAg-TBK1 Axis Suppresses IFN-I and Induces Autophagy in HBV Infection provides a concise overview of the same study’s immune-evasion model. The present analysis extends that summary by emphasizing the separation between TBK1 phosphorylation and IRF3 activation, the role of TBK1 dimerization, and the distinction between autophagosome accumulation and incomplete autophagic flux.

A second resource, BX795: ATP-Competitive PDK1 Inhibitor for Cancer and Immunity Research, places BX795 within PDK1, TBK1, and IKKε assay contexts. That article is useful for compound-oriented pathway planning, whereas the reference study provides the disease-specific biological rationale. Read together, they support careful experimental separation of reagent pharmacology from the HBV mechanism demonstrated in the paper.

Limitations and Transferability

Several limitations should guide interpretation. First, HBsAg expression systems, transgenic mice, and chronic patient samples represent complementary but nonidentical models. They may differ in antigen abundance, viral replication status, inflammatory context, and hepatocyte state. Findings from an HBsAg-focused model should therefore not automatically be generalized to every phase of natural HBV infection.

Second, BX795 is pharmacologically informative but not perfectly target-exclusive in a cellular setting. Its use supports involvement of TBK1-sensitive signaling, yet target attribution would be stronger when combined with TBK1 depletion, rescue, kinase-domain mutants, or other orthogonal approaches. This is particularly important when interpreting effects on interferon production, autophagy, and viral replication simultaneously.

Third, incomplete autophagy is a functional interpretation that depends on measuring multiple stages of the pathway. Accumulated autophagosomes can reflect increased formation, blocked clearance, or both. The study’s SNAP29 and fusion results strengthen the incomplete-flux model, but future work should continue to distinguish altered vesicle trafficking from generalized lysosomal dysfunction.

Finally, the findings establish a compelling immune-evasion mechanism but do not demonstrate that pharmacologically blocking the HBsAg–TBK1 interaction would be clinically sufficient. TBK1 participates in several host-defense pathways, and prolonged interference could affect antiviral protection or other cellular functions. The most transferable contribution of the paper is therefore its mechanistic framework: analyze how viral proteins redistribute signaling complexes and pair kinase measurements with functional flux and tissue-level validation.

Research Support Resources

Researchers reproducing related TBK1 or PDK1 inhibitor workflows can use BX795 (SKU A8222) as a small-molecule kinase perturbant. The product information reports ATP-competitive inhibition of PDK1 with an IC₅₀ of 6–11 nM, as well as activity against TBK1 and IKKε; these values should be treated as assay-context specifications rather than direct measures of potency in HBV-infected cells. For studies based on the reference paper, appropriate controls should preserve the distinction between TBK1-dependent inhibition of interferon signaling and BX795’s broader kinase profile.